Page last updated: 2024-09-05

erlotinib hydrochloride and Abnormalities, Drug-Induced

erlotinib hydrochloride has been researched along with Abnormalities, Drug-Induced in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A	1

Reviews

1 review(s) available for erlotinib hydrochloride and Abnormalities, Drug-Induced

Article	Year
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?]. Bulletin du cancer, 2016, Volume: 103, Issue:5 Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk	2016

Article

Year

[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].

Bulletin du cancer, 2016, Volume: 103, Issue:5

Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk

2016